吉林敖东：控股子公司盐酸纳洛酮注射液药品补充申请获批

Core Viewpoint - Jilin Aodong Pharmaceutical Group's subsidiary has received approval for the "Naloxone Hydrochloride Injection" from the National Medical Products Administration, indicating a significant advancement in the company's product offerings and potential market impact [1] Group 1: Product Approval - The company announced that its subsidiary, Jilin Aodong Pharmaceutical Group Yanji Co., Ltd., has received a "Drug Supplement Application Approval Notice" for Naloxone Hydrochloride Injection [1] - The drug has passed the consistency evaluation of quality and efficacy for generic drugs, which is crucial for market entry and competitiveness [1] Group 2: Drug Indications - Naloxone Hydrochloride Injection is indicated for use in opioid-related anesthesia recovery, specifically to counteract respiratory depression caused by opioids, facilitating patient awakening [1] - The drug is also used to completely or partially reverse respiratory depression caused by opioid overdose, highlighting its critical role in emergency medical situations [1]